510(k) device
EyeArt
Eyenuk, Inc. · Diabetic Retinopathy Detection Device (PIB, Class II) · First FDA decision Aug 3, 2020, newest Aug 3, 2020DiabetesMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "EyeArt"
MAUDE reports
0
Brand "EyeArt", since 2015
PubMed studies
38
Mentioning "EyeArt"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EyeArt
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EyeArt510(k)
K200667 · Decided Aug 3, 2020 · 143 days after receipt
Device type: Diabetic Retinopathy Detection Device (PIB) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EyeArt", any status and sponsor, newest update first.
No registered device study names "EyeArt".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EyeArt", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PIB
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EyeArt"[tiab]. The summary above synthesizes these.
- Effectiveness of artificial intelligence for diabetic retinopathy screening in community in Binh Dinh Province, Vietnam.
Van TN, Thi HLV · Taiwan J Ophthalmol · 2024
- Diabetic Retinopathy Screening Using Smartphone-Based Fundus Photography and Deep-Learning Artificial Intelligence in the Yucatan Peninsula: A Field Study.
Wroblewski JJ, Sanchez-Buenfil E, Inciarte M, et al. · J Diabetes Sci Technol · 2025
- [Use of Artificial Intelligence in Diabetic Retinopathy Screening: Experience in a Health Service in Santiago, Chile].
Ibañez-Bruron MC, Cruzat A, Ordenes-Caviere G, et al. · Rev Med Chil · 2024English Abstract
- EyeArt artificial intelligence analysis of diabetic retinopathy in retinal screening events.
Vought R, Vought V, Shah M, et al. · Int Ophthalmol · 2023
- Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-Threatening Diabetic Retinopathy.
Ipp E, Liljenquist D, Bode B, et al. · JAMA Netw Open · 2021Clinical Trial, Multicenter Study
- Modern Approach to Diabetic Retinopathy Diagnostics.
Kipa M, Koryciarz I, Kustosik N, et al. · Diagnostics (Basel) · 2024Review
- Diagnostic Accuracy of EyeArt for Fundus-Based Detection of Diabetic Retinopathy: A Systematic Review and Meta-analysis.
Wang TW, Luo WT, Tu YK, et al. · Am J Ophthalmol · 2026Systematic Review, Meta-Analysis
- Diagnostic accuracy of diabetic retinopathy grading by an artificial intelligence-enabled algorithm compared with a human standard for wide-field true-colour confocal scanning and standard digital retinal images.
Olvera-Barrios A, Heeren TF, Balaskas K, et al. · Br J Ophthalmol · 2021Comparative Study, Research Support, Non-U.S. Gov't
- Automated Diabetic Retinopathy Image Assessment Software: Diagnostic Accuracy and Cost-Effectiveness Compared with Human Graders.
Tufail A, Rudisill C, Egan C, et al. · Ophthalmology · 2017Comparative Study, Observational Study
- An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness.
Tufail A, Kapetanakis VV, Salas-Vega S, et al. · Health Technol Assess · 2016Observational Study
- Artificial Intelligence Detection of Diabetic Retinopathy: Subgroup Comparison of the EyeArt System with Ophthalmologists' Dilated Examinations.
Lim JI, Regillo CD, Sadda SR, et al. · Ophthalmol Sci · 2023
- Comparison of automated and expert human grading of diabetic retinopathy using smartphone-based retinal photography.
Kim TN, Aaberg MT, Li P, et al. · Eye (Lond) · 2021Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code PIB.
- Aeye-DsAeye Health, Inc. · 510(k) 2024
- iPredict-DRiHealthscreen, Inc. · 510(k) 2026
- EyeArt v2.2.0Eyenuk, Inc. · 510(k) 2023
- IDx-DR v2.3Digital Diagnostics, Inc. · 510(k) 2022
- IDx-DRDigital Diagnostics, Inc. · 510(k) 2021
- IDx-DRIdx, LLC · De Novo 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.